Aurinia Pharmaceuticals Inc (NASDAQ:AUPH)
North American company
Share Price Chart
- Chart currently unavailable -
Market Info - AUPH
- Market Open Price0.00
- Previous Close0.00
- Volume-
- 52w Low/High-
- Last Trade Price0.00
- Bid/Ask Price0.00
Company Info - AUPH
- Market Cap$1.818bn
- SymbolNASDAQ:AUPH
- IndustryHealthcare
- SectorBiotechnology
- Currency
- ISINCA05156V1022
Company Profile
Aurinia Pharmaceuticals Inc is a biopharmaceutical company. It provides products for patients suffering from serious diseases with a high unmet medical need. The firm is developing voclosporin, an investigational drug, for the treatment of lupus nephritis (LN), focal segmental glomerulosclerosis (FSGS), and Dry Eye Syndrome (DES). Geographically, it derives maximum revenue from the United States followed by China.Aurinia Pharmaceuticals Inc is a clinical stage pharmaceutical company. The firm is engaged in the development of a therapeutic drug to treat autoimmune diseases, in particular lupus nephritis.
Latest AUPH news
Currently there for this company. Visit our news hub for other news .